Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $8.9 million.

  • Gossamer Bio's Cash & Equivalents fell 6861.65% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 6861.65%. This contributed to the annual value of $46.1 million for FY2024, which is 4349.25% up from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Cash & Equivalents is $8.9 million, which was down 6861.65% from $26.3 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's Cash & Equivalents peaked at $153.5 million during Q3 2022, and registered a low of $8.9 million during Q3 2025.
  • Moreover, its 4-year median value for Cash & Equivalents was $46.1 million (2024), whereas its average is $65.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 7132.43% in 2023, then surged by 13477.73% in 2024.
  • Over the past 4 years, Gossamer Bio's Cash & Equivalents (Quarter) stood at $112.0 million in 2022, then plummeted by 71.32% to $32.1 million in 2023, then surged by 43.49% to $46.1 million in 2024, then crashed by 80.61% to $8.9 million in 2025.
  • Its Cash & Equivalents was $8.9 million in Q3 2025, compared to $26.3 million in Q2 2025 and $29.0 million in Q1 2025.